Novo Nordisk expects a decline in sales of up to 13 per cent this year as the Danish drugmaker competes in an increasingly crowded obesity-treatment market and faces pressure on the pricing of its drugs.
丹麦药企诺和诺德(Novo Nordisk)预计今年销售额将最多下滑13%。随着肥胖治疗市场日益拥挤、其药品面临价格下压。
您已阅读6%（264字），剩余94%（4482字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。